Anatomy of melancholia: Focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin

Journal of Anatomy

Volumn 207, Issue 3, 2005, Pages 259-264

  Dinan, Timothy G ^a   Scott, Lucinda V ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

ACTH; Cortisol; Hypothalamus; Stress; Vasopressin

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DESMOPRESSIN; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; VASOPRESSIN; VASOPRESSIN V3 RECEPTOR;

ADENOHYPOPHYSIS; ADRENAL HYPERPLASIA; AUTOPSY; CLINICAL FEATURE; CORTICOSTEROID BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; DRUG ACTIVITY; DRUG INFUSION; DRUG RECEPTOR BINDING; HORMONE RELEASE; HUMAN; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; MAJOR DEPRESSION; MELANCHOLIA; MONOAMINE NERVE CELL; NEGATIVE FEEDBACK; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT;

ADRENOCORTICOTROPIC HORMONE; DEPRESSIVE DISORDER; FEEDBACK, BIOCHEMICAL; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NEURONS; PITUITARY-ADRENAL SYSTEM; RECEPTORS, VASOPRESSIN; STRESS, PSYCHOLOGICAL; VASOPRESSINS;

EID: 24944571838     PISSN: 00218782     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-7580.2005.00443.x     Document Type: Review

References (43)

1. Aguilera G, Rabadan-Diehl C (2000) Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 96, 23-29.
2. Antoni F, Fink G, Sheward W (1990) Corticotrophin-releasing peptides in rat hypophysial portal blood after paravedntricular lesions: a marked reduction in the concentration of 41-residue corticotropin-releasing factor, but no change in vasopressin. J Endocrinol 125, 175-183.
3. Antoni FA (1993) Vasopressinergic control of pituitary-adrenal secretion comes of age. In Frontiers in Neuroendocrinology, pp. 76-122. New York: Raven Press.
4. Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab 1, 406-410.
5. von Bardeleben U, Holsboer F (1989) Cortisol response to a combined dexamethasone-human corticotropin-releasing hormone challenge in patients with depression. J Neuroendocrinol 1, 485-488.
6. Carroll BJ (1972) The hypothalamicc pituitary adrenal axis in depression. In Depressive Illness. Some Research Studies (eds Davies B, Carroll PW, Mowbray R), pp. 23-201. Springfield, IL: C C. Thomas.
7. Chao HM, Choo P, McEwen B (1989) Glucocorticoid and mineralocorticoid receptor mRNA expression in the rat brain. Neuroendocrinology 50, 365-371.
8. Cole MA, Kim PJ, Kalman BA, Spencer RL (2000) Dexamethasone suppression of cortciosteroid secretion: evaluation of the site of action by receptor measures and functional studies. Psychoneuroendocrinology 25, 151-167.
9. De Bold CR, Sheldon WR, DeCherney GS, et al. (1984) Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor. J Clin Invest 73, 533-538.
10. De Goeij D, Djikstra H, Tilders F (1992) Chronic psychosocial stress enhances vasopressin but not corticotropin-releasing factor, in the external zone of the median eminence of male rats: relationship to subordinate status. Endocrinology 131, 847-853.
11. Dinan TG (1994) Glucocorticoids and the genesis of depressive illness: a psychobiological model. Br J Psychiatry 164, 365-371.
12. Dinan TG, Lavelle E, Scott L, Medbak S, Grossman A (1999) Desmopressin normalises the blunted ACTH response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. J Clin Endocrinol Metab 84, 2238-2246.
13. Dinan TG, O'Brien S, Lavelle E, Scott LV (2004) Further neuroendocrine evidence of enhanced V3 receptor responses in melancholic depression. Psychol Med 34, 169-172.
14. Favrod-Coune C, Raux-Demay M, Proeschel M, Bertagna X, Girard F, Luton JP (1993) Potentiation of the classic ovine corticotropin-releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin. Clin Endocrinol 38, 405-410.
15. Gjerris A, Hammer M, Vendsborg P, Christensen NJ, Rafaelsen OJ (1985) Cerebrospinal fluid vasopressin - changes in depression. Br J Psychiat 147, 696-701.
16. Grazzini E, Lodboerer AM, Perez-Martin A, Joubert D, Guillon G (1996) Molecular and functional characterization of the V1b receptor in rat adrenal medulla. Endocrinology 137, 3906-3914.
17. Heuser I, Yassouridis A, Holsboer F (1994) The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Affect Dis 4, 93-101.
18. Inder WJ, Swanney MP, Donald RA, Prickett TC, Hellemans J (1998) The effect of glycerol and desmopressin on exercise performance and hydration in triathletes. Med Sci Sports Exerc 30, 1263-1269.
19. Jakobsen T, Blomenthal M, Hagman H, Heikkinen E (1969) The diurnal variation of urinary and plasma 17-hydroxy-corticosteroid (17-OHCS) levels and plasma 17-OHCS response to lysine-8-vasopressin in depressive patients. J Psychosom Res 13, 363-375.
20. Jard S, Gaillard R, Guillon G, et al. (1987) Vasopressin receptor antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis. Molec Pharmacol 30, 171-180.
21. Jia L-G, Canny B, Orth D, Leong D (1991) Distinct class of corticotropes mediate corticotropin-releasing hormone and arginine vasopressin-stimulated adrenocorticotropin release. Endocrinology 128, 197-203.
22. Kathol R, Jaeckle R, Lopez J, Meller W (1989) Consistent reduction of ACTH responses to stimulation with CRH, vasopressin and hypoglycaemia in patients with major depression. Br J Psychiatry 155, 468-478.
23. Keller-Wood M, Dallman M (1984) Corticosteroid inhibition of ACTH secretion. Endocr Rev 5, 1-23.
24. Krahn DD, Meller WH, Shafer RB, Morley JE (1985) Cortisol response to vasopressin in depression. Biol Psychiatry 20, 918-921.
25. Liu JP, Clarke IJ, Funder JW, Engler JD (1994) Studies of the secretion of corticotropin-releasing factor and arginine vasopressin into the hypophyseal-portal circulation of the conscious sheep. II. The central noradrenergic and neuropeptide pathways cause immediate and prolonged hypothalamic-pituitary-adrenal activation: potential involvement in the pseudo-Cushing's syndrome of endogenous depression and anorexia nervosa. J Clin Invest 93, 1439-1450.
26. Ma XM, Lightman S, Aguilera G (1999) Vasopressin and corticotropin-releasing hormone gene responses to novel stress in rats adapted to repeated restraint. Endocrinology 140, 3623-3632.
27. Meller WH, Kathol RC, Jaeckle RS, Lopez JF (1987) Stimulation of the pituitary-adrenal axis with arginine vasopressin in patients with depression. J Psychiat Res 21, 269-277.
28. Mouri T, Itoi K, Takahashi K, et al. (1993) Co-localization of corticotropin-releasing factor and vasopressin in the paraventricular nucleus of human hypothalamus. Neuroendocrinology 57, 34-39.
29. Muller MB, Landgraf R, Keck M (2000) Vasopressin, major depression, and hypothalamic-pituitary-adenocortical desensitization. Biol Psychiatry 48, 330-333.
30. Plotsky P (1991) Pathways to the secretion of adrenocortictropin: a view from the portal. J Neuroendocrinol 3, 1-9.
31. Purba J, Hoogendijk W, Hoffman M, Swaab D (1996) Increased numbers of vasopressin- and oxytocin-containing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psych 53, 137-143.
32. Raadsheer FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF (1994) Increased number of corticotropin-releasing hormone neurons in the hypothalamic paraventricular nuclei of depressed patients. Neuroendocrinology 60, 436-444.
33. Rabadan-Diehl C, Lolait S, Aguilera G (1995) Regulation of the pituitary V1b receptor mRNA during stress in the rat. J Neuroendocrinol 7, 903-910.
34. Robertson G (1992) In The Kidney: Pathophysiology and Pathophysiology, 2nd edn. (eds Selden D, Giebisch C), pp. 1595-1613. New York: Raven Press.
35. Rubin R, Dinan TG, Scott LV (2001) The neuroendocrinology of affective disorders. In Hormones, Brain and Behaviour (eds Pfaff D, Arnold AP, Etgen AM, Fahrbach SE, Moss RL, Rubin RT), pp. 467-514. New York: Academic Press.
36. Salata RA, Jarrett DB, Verbalis JG, Robinson AG (1988) Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH. J Clin Invest 81, 766-774.
37. Tizabi Y, Aguilera G (1992) Desensitization of the hypothalamic-pituitary-adrenal axis following prolonged administration of corticotropin-releasing hormone and vasopressin. Neuroendocrinology 56, 611-618.
38. Tribollet E, Barberis C, Dubois-Dauphin M, Dreifuss JJ (1992) Localization and characterization of binding sites for vasopressin and oxytocin in the brain of the guinea pig. Brain Res 589, 15-23.
39. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterisation of a 41 residue ovine hypothalamic peptide that stimulates secretion of the corticotropin and beta-endorphin. Science 213, 1394-1399.
40. Van Londen L, Goekoop J, van Kempen G, Frankhuijzen-Sierevogel A, Wiegant V, De Wied D (1997) Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17, 284-292.
41. Whitnall M (1987) Vasopressin co-exists in half of the corticotropin-releasing factor neurones in the external zone of the median eminence in normal rats. Neuroendocrinology 45, 420-424.
42. Whitnall M (1989) Stress selectively activates the vasopressin-containing subset of corticotropin-releasing hormone neurons. Neuroendocrinology 50, 702-707.
43. Zhou JN, Hofman MA, Swaab DF (1996) Morphometric analysis of vasopressin and vasoactive intestinal polypeptide neurons in the human suprachiasmatic nucleus: influence of microwave treatment. Brain Res 742, 334-338.